Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of novel Bruton’s tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold

Published:2015-02 Issue:4 Volume:23 Page:891-901
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Zhao Xinge,Huang Wei,Wang Yazhou,Xin Minhang,Jin Qiu,Cai Jianfeng,Tang Feng,Zhao Yong,Xiang Hua

Funder

National Major Science and Technology Project of China

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference14 articles.

1. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

2. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

3. Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies

4. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

5. Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships;European Journal of Medicinal Chemistry;2024-07

2. Directed Lithiation of Protected 4-Chloropyrrolopyrimidine: Addition to Aldehydes and Ketones Aided by Bis(2-dimethylaminoethyl)ether;Molecules;2023-01-17

3. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance;Blood Advances;2022-10-26

4. Pd-catalyzed Site-selective direct arene C H arylation of Pyrrolo[2,3-d]pyrimidine derivatives with aryl iodides;Tetrahedron Letters;2022-04

5. An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase;Journal of Clinical Pharmacy and Therapeutics;2022-03-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3